Methodology challenge: notebook 'Mitochondrial transfer between neurons and glia — Rich Analysis Notebook' — evaluate design, statistical methods, and reproducibility.

Theorist position for analysis SDA-2026-04-27-gap-methodol-20260427-035148-7b3b3df4: Methodology challenge: notebook 'Mitochondrial transfer between neurons and glia — Rich Analysis Notebook' — evaluate design, statistical methods, and reproducibility.

Context: Target artifact: type=notebook id=notebook-nb-top5-01231108. Scheduled personas: methodologist, statistician, replicator.

Primary claim: whether the Mitochondrial transfer between neurons and glia — Rich Analysis Notebook notebook design supports reproducible mechanistic inference is a debate-worthy mechanism or quality claim, not just a restatement of the analysis title. The strongest version predicts a proximal readout that changes before a late outcome. For this methodology challenge, the debate should preserve the named strata and entities: Methodology, challenge, Mitochondrial, transfer, between, neurons.

The constructive hypothesis is that the analysis can advance SciDEX's world model if it binds the question to a falsifier. The priority test is rerun the notebook from a clean environment, freeze inputs and random seeds, audit all statistical contrasts, and require an independent replication table. A positive result would require concordant movement of the proximal readout and a disease-relevant or reproducibility-relevant endpoint; a negative result would downgrade the claim rather than merely mark the analysis as inconclusive.

For the downstream Atlas and Exchange layers, the useful artifact is a debated hypothesis with explicit evidence requirements, not a generic confidence score. The claim should therefore carry a clear action: validate the mechanism, strengthen the benchmark, or revise the preregistered target based on the specified falsifier.

Skeptic critique for analysis SDA-2026-04-27-gap-methodol-20260427-035148-7b3b3df4: Methodology challenge: notebook 'Mitochondrial transfer between neurons and glia — Rich Analysis Notebook' — evaluate design, statistical methods, and reproducibility.

The analysis question is substantive, but the current record does not by itself prove the claim. The main dissent is: the notebook may contain useful exploratory signals but still overstate causality if controls, multiple-testing correction, provenance, or environment capture are weak.

The debate should reject overclaiming in three forms. First, association or benchmark performance should not be treated as causality without a design that separates cause from consequence. Second, a positive average effect can hide subgroup failure across Methodology, challenge, Mitochondrial, transfer, between, neurons. Third, an analysis that lacks provenance, environment capture, or preregistered endpoints can produce plausible but non-reproducible conclusions.

A decisive falsifier would be failure of rerun the notebook from a clean environment, freeze inputs and random seeds, audit all statistical contrasts, and require an independent replication table to move the predicted proximal endpoint under adequate power and controls. The strongest alternative explanation is that the observed signal is a disease-stage marker, prompt or notebook artifact, or compensatory response rather than an upstream driver.

Domain expert assessment for analysis SDA-2026-04-27-gap-methodol-20260427-035148-7b3b3df4: Methodology challenge: notebook 'Mitochondrial transfer between neurons and glia — Rich Analysis Notebook' — evaluate design, statistical methods, and reproducibility.

The practical path is staged. Stage 1 should lock the data inputs, covariates, and endpoints. Stage 2 should run the most direct validation: rerun the notebook from a clean environment, freeze inputs and random seeds, audit all statistical contrasts, and require an independent replication table. Stage 3 should connect the result to a reusable SciDEX artifact: a promoted hypothesis, a benchmark row with confidence intervals, a notebook reproducibility badge, or a revised preregistration.

Feasibility is moderate because the question is specific enough to test, but the intervention point may be less direct than the named entity. For therapeutic claims, safety and timing matter; for benchmark and methodology claims, calibration, reproducibility, and leakage controls matter. The near-term deliverable should be a falsifiable validation plan rather than a premature declaration of success.

Consensus is strongest around using this analysis to sharpen the world model. Dissent remains around causal direction, artifact robustness, and translational tractability.